A Case of Iron Deficiency Anemia with Co-existing Hb Fontainebleau
Abhishek Purohit1, Mukul Aggarwal1, Roshan B Colah2, Anita H Nadkarni2 and Hara P Pati1
Department of Hematology, All India Institute of Medical Sciences, New
2 Institute of Immunohaematology, Haematogenetics. Mumbai, Maharashtra, India.
Received: May 2, 2014
Accepted: June 11, 2014
Meditterr J Hematol Infect Dis 2014, 6(1): e2014051, DOI 10.4084/MJHID.2014.051
This article is available on PDF format at:
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hb Fontainebleau is a rare alpha chain variant in the Indian population which generates an unknown peak on hemoglobin HPLC study and does cause diagnostic difficulty to those who are not acquainted with this entity. We present a case of Hb Fontainebleau, an eighteen year old patient who presented with symptoms related to anemia to our department and unknown peak observed in HPLC plots lead us to family study and molecular characterization for this case.
one of the most common human genetic abnormalities known, is inherited
as an autosomal recessive disorder. They have clinical phenotype
varying from almost asymptomatic to a lethal haemolytic anemia and can
occur due to deletional or non-deletional mutations. Non-deletional
alpha thalassemias are relatively rare, and cause more severe anemia
clinically. Hb Fontainebleau is one of the rarely reported clinically
asymptomatic α chain variants.
It shows a
characteristic retention time on hemoglobin HPLC (High-performance
liquid chromatography) which may cause diagnostic dilemma if one is
unaware of its pattern. We are reporting a case of Hb Fontainebleau,
who attended our hematology clinic for symptoms related to anemia. This
patient represents the sixth case of this alpha chain variant reported
An eighteen year old Punjabi male born to a non-consanguineous marriage
presented to hematology department with two year history of weakness
and easy fatigability. His past and family history was not significant.
Physical examination revealed pallor only. There was no icterus,
lymphadenopathy or hepatosplenomegaly. Systemic examination did not
reveal any abnormality.
Laboratory investigation revealed hemoglobin 7.2 g/dL, total leucocyte count 6.01 x 109/L with normal differential count and platelet count 141 x 109/L. Peripheral smear examination revealed microcytic hypochromic red cells with mean corpuscular volume (MCV) 68.9 fL, mean corpuscular hemoglobin (MCH) 15.8 pg and mean corpuscular hemoglobin concentration (MCHC) being 22.9 g/dL and red cell count 4.56 x 1012/L. His serum ferritin was 10 ng/ml; serum iron was 12 μg/dL, total iron binding capacity was 589 μg/dL, unbound iron binding capacity was 587 μg/dL and transferrin saturation was 2.03%. HPLC analysis (BioRad, Beta thalassaemia short program) on the patient’s blood revealed 13.8% of an unknown hemoglobin with retention time of 2.92 minutes which appeared as a hump in the peak adjoining Hb A (Figure 1).
|Figure 1. High-performance liquid chromatography chromatogram showing the unknown peak at retention time 2.92 minutes|
other hemoglobins on HPLC were 77.6% of Hb A, 2.3% of Hb A2 and 1.2% of
Hb F. Cellulose acetate electrophoresis (pH 8.9) did not show any
abnormal band. HPLC of the parental samples was performed which
revealed the presence of a similar 11.6% unknown hemoglobin with
retention time 2.87 minutes in the mother. Her hemoglobin was 10.3 g/dL
with MCV 81.7 fL, MCH 25.1 pg and MCHC 307 g/L red cell count 4.10 x 1012/L. Father
had hemoglobin of 12.0 g/dL with MCV 59.0 fL, MCH 18.6 pg and MCHC 315
g/L red cell count 6.46 x 1012/L.
His HPLC analysis revealed raised Hb A2 (5.4%) suggesting heterozygous
Molecular characterization was done by automated DNA sequencing on the ABI Prism 310 DNA sequencer (Applied Systems, Foster City, CA, USA.) showing presence of a heterozygous G>C substitution at codon 21 (alpha 2 globin gene) leading to the substitution of alanine to proline at the beginning of the beta helix in the alpha chain corresponding to Hb Fontainebleau in the index case, his mother and two sisters (Figure 2). The father was heterozygous for beta thalassaemia with the CD 8/9(+G) mutation. The patient was treated with oral iron supplements due to low ferritin levels and responded well to therapy with relief of symptoms and increase in hemoglobin on the subsequent evaluation.
|Figure 2. Electropherogram of the alpha gene showing hemoglobin Fontainebleau [Alpha 21(B2) α2Ala>Pro].|
Mutations that cause alpha thalassemia can be deletional or
non-deletional types. Non-deletional alpha thalassemias are relatively
rare, result in more severe anaemia and are because of a variety of
mutations including punctual substitutions and small insertions ⁄
deletions. The majority of these
found to involve the upstream α2 globin gene proximal to the
erythroid-specific regulatory region called multispecies conserved
Many mutations have been described affecting mRNA processing, mRNA translation, and α-globin stability. Hb Fontainebleau [alpha 21 (B2) Ala> Pro, HBA2: c 64G>C] is an alpha chain variant characterized by an alanine→proline substitution at codon 21 with a GCT>CCT change at the DNA level, this proline residue is located at the beginning of the beta helix. Literature search reveals only five reported cases of Hb Fontainebleau worldwide, including two cases from India.[5-8]
The first reported case of Hb Fontainebleau was that of an adolescent female of Italian origin, who had severe anemia. However, this severity was explained by the co-existing membrane defect, spherocytosis with Hb Fontainebleau.
This hemoglobin variant has electrophoretic properties identical to those of Hb A with the exception of isoelectrofocusing in which it migrates like Hb A1c. The introduction of a prolyl residue at the beginning of the B helix in the alpha chain does not lead to a change in the stability or oxygen binding properties of the hemoglobin molecule.
With identification of a second case it was observed that although slightly unstable, this variant was expressed at 28-29% of the total and was caused by a heterozygous mutation in the alpha2 gene. This second reported case was an adult Iraqi male, living in New Zealand. The third case was seen during thalassemia screening in the Greek Cypriot population in Cyprus. Upadhye et al., in their newborn screening for sickle cell disorders, identified a baby with Hb Fontainebleau in a compound heterozygous state with Hb S and the baby had anemia at birth (Hb 11.4 g/dL), however had no cyanosis, icterus or need for transfusion. The second case from India was a 35 year old lady, a case of secondary infertility who presented for routine antenatal screening program for thalassemia and had normal hematological indices. The present case was different from other reported cases from India as it was not part of a screening programme, but rather presented due to his moderately severe anemia. However causal relationship of anemia with Hb Fontainebleau cannot be established as he responded well to iron supplements and achieved near normal hemoglobin level. Further, his mother and both the sisters were asymptomatic.
Hb Fontainebleau is a rare alpha chain variant in the Indian population. It generates an unknown peak on HPLC and can cause diagnostic difficulty for those who are not acquainted with this entity. However this produces no symptoms of anemia so a patient presenting with anemia and Hb Fontainebleau should be investigated for other causes of anemia and counseled properly.
- Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010;5:13. http://dx.doi.org/10.1186/1750-1172-5-13 PMid:20507641 PMCid:PMC2887799
- Bain BJ. Haemoglobinopathy Diagnosis, 2nd edn. Malden, MA: Blackwell Publishing; 2006:66. http://dx.doi.org/10.1002/9780470988787
- Orkin SH, Goff SC, Hechtman RL. Mutation in
an intervening sequence splice junction in man. Proc Natl AcadSci USA
- Wajcman H et al. Hb Fontainebleau [alpha 21(B2)Ala----pro], a new silent mutant hemoglobin. Hemoglobin. 1989;13(5):421-8. http://dx.doi.org/10.3109/03630268908998081 PMid:2599878
- Brennan SO, Chan T, Ryken S, Ruskova A.A
second case of Hb Fontainebleau [alpha21(B2)Ala-->Pro] in an
individual with microcytosis. Hemoglobin 2009;33(3):258-61. http://dx.doi.org/10.1080/03630260903061135 PMid:19657841
- Kyrri AR, Felekis X, Kalogerou E, Wild BJ,
Kythreotis L, Phylactides M, et al. Hemoglobin variants in Cyprus.
Hemoglobin. 2009;33:81-94. http://dx.doi.org/10.1080/03630260902813502 PMid:19373583
- Upadhye DS et al. First case of Hb
Fontainebleau with sickle haemoglobin and other non-deletional a gene
variants identified in neonates during newborn screening for sickle
cell disorders. J Clin Pathol. 2012 Jul;65(7):654-9. http://dx.doi.org/10.1136/jclinpath-2011-200642 PMid:22461654
- Mashon RS, Nair S, Sawant P, Colah RB, Ghosh K, Das S. Hemoglobin Fontainebleau [a21(B2)Ala>Pro]: The second report from India. Indian J Hum Genet. 2013 Jul;19(3):352-4. http://dx.doi.org/10.4103/0971-6866.120822 PMid:24339552 PMCid:PMC3841564